|
|
Abelcet - Newsfeeds
-
-
Buell, M.D., to Chair the Scientific Advisory Board (SAB) committee overseeing the development of iCo-009, iCo's oral Amphotericin B program for life-threatening fungal and parasitic diseases. Dr. Buell was most recently the Senior Medical Director at ...
-
-
The first product under development using the technology is Bioral Amphotericin B. The Company's headquarters is located in Raleigh, North Carolina. For more information please visit www.bdsi.com. BDSI(R), BEMA(R) and Bioral(R) are registered trademarks of ...
-
-
The first product under development using the technology is Bioral Amphotericin B. The Company’s headquarters is located in Raleigh, North Carolina. For more information please visit www.bdsi.com . This press release and the statements of representatives ...
-
-
Drugs that are known to cause fever include biological response modifiers, amphotericin B, and bleomycin. Suspected drug-related fever may be treated by stopping the drug that is causing the fever. When a biological response modifier, certain chemotherapy ...
-
-
We incurred a net and comprehensive loss of $803,932 for the three months ended June 30, 2010 compared to a net and comprehensive loss of $556,886 for the three months ended June 30 2009, representing an increase of approximately $247,046. The increase in ...
-
-
LOURES, Portugal , September 14, 2010 /PRNewswire/ -- Hovione is announcing the approval in Japan of Inavir(R), Dry Powder Inhaler 20mg, for treatment of influenza. This approval has been granted to Daiichi Sankyo Company Ltd, a licensee of Hovione for the ...
-
-
BEDMINSTER, N.J., Oct. 26 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, announced today that an analysis of two pivotal safety and efficacy studies of CAMBIA(TM) (diclofenac potassium for oral solution ...
-
-
Andrew Rae presented at the Dundee Capital Markets Emerging Growth Conference on November 15th in Toronto, ON. -- iCo's oral Amphotericin B program was the subject of two poster presentations at the November 15th-17th International Pharmaceutical ...
-
-
BioVex announced that a Phase 3 study with OncoVEX GM-CSF vaccine for the first line treatment of patients with locally advanced squamous cell carcinoma of the head & neck (SCCHN) has commenced. The study design agreed with the FDA under the Special ...
-
-
Enzon, Inc. (Nasdaq:ENZN) today announced that the Company will suspend its PEG-paclitaxel development program. The decision to suspend the program, which is in Phase I, is based on a strategic analysis of the program's potential investment returns against ...
-
-
The Company has a portfolio of four marketed products, Oncaspar[R], DepoCyt[R], Abelcet[R] and Adagen[R]. EnzonEs drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the ...
-
-
That was its highest price since December 2007. The specialty drugs sigma-tau is buying are cancer drug Oncaspar, fungal infection treatment Abelcet, meningitis drug DepoCyt, and Adagen, which is used for severe combined immunodeficiency disease, or ...
-
-
It is selling off Oncaspar, Adagen, DepoCyt and Abelcet in the deal--which includes $27 million in milestones--with a U.S. subsidiary of sigma-tau. "Enzon's board of directors is evaluating options to return most of the value of this sale to shareholders ...
-
-
The iCo-009 is a proprietary oral formulation of amphotericin B for treatment of systemic gungal infections in immune-compromised patients such as human immunodeficiency virus (HIV)/acquired immune deficiency syndrome ...
-
-
... reduction of ergosterol content in the YER067W deleted strain explained the observed 2- and 4-fold increase in resistance to the drugs fluconazole and amphotericin B, respectively. Cell fractionation and ...
-
-
Vets administer some - such as amphotericin B - via IV. Others like ketoconazle can be swallowed. Some cats require both types of dosing. The prognosis of a case of blastomycosis depends on several factors.
-
-
The first product under development using the technology is Bioral Amphotericin B. The Company's headquarters is located in Raleigh, North Carolina. For more information please visit www.biodeliverysciences.com. BDSI ®, BEMA ® and Bioral ® are ...
-
-
The first product under development using the technology is Bioral Amphotericin B. The Company’s headquarters is located in Raleigh, North Carolina. For more information please visit www.biodeliverysciences.com .
-
-
They are Oncaspar, a leukemia treatment; Adagen, a treatment for severe combined immunodeficiency disease, also known the "Bubble Boy Disease;" DepoCyt, a meningitis drug; and Abelcet, for treating invasive fungal infections in patients with ...
-
-
The Company has a portfolio of four marketed products: Oncaspar, DepoCyt, Abelcet and Adagen. Enzon’s drug development programs utilize several approaches, including its PEGylation technology platform and the Locked Nucleic Acid (LNA) technology.
Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.
Pages:
1
2
Next
|
|
